Cost Variation Analysis of Metformin-Based Dual Fixed-Dose Combinations Prescribed in India
Abstract
Background: Metformin is the initial pharmacological intervention for managing type 2 diabetes mellitus (T2DM). However, its effectiveness for achieving optimal glycemic control diminishes over time, requiring the addition of other oral antidiabetic drugs (OADs) to the treatment regimen. The widespread adoption of metformin-based fixed-dose combinations (FDCs) in India necessitates an investigation into their impact on affordability and access. This study, therefore, undertook a cost variation analysis of available dual FDCs containing 500 mg of metformin to illuminate these implications.
Methods: The cost data were sourced from retail websites. We analyzed cost variation by calculating the cost variation percentage (CV%) and the average cost of all FDCs. The relationship among cost variation, average cost, and the number of manufacturing companies was statistically assessed using Pearson's correlation in Microsoft Excel.
Results: Among the 15 FDCs analyzed, the metformin + dapagliflozin combination exhibited the most substantial cost variation, reaching 436.2%. Conversely, the metformin + saxagliptin combination recorded the highest average cost per tablet, at 45.16 rupees (equivalent to 0.52$). A statistically significant negative Pearson's correlation was observed between the average cost of drugs and the number of manufacturing companies across all FDCs (r = −0.595, p = 0.019*) and in the metformin + dipeptidyl peptidase-4 inhibitors (DPP4is) group (r = −0.900, p = 0.037*).
Conclusion: In our study, the co-administration of metformin with the newer therapeutic agents (dapagliflozin and saxagliptin) demonstrated the highest variability in pharmaceutical pricing. This finding underscores the necessity for regulatory intervention regarding the costs of these FDCs within the Indian market.
International Diabetes Federation (2021). IDF Diabetes Atlas. 10th ed. Brussels, Belgium.
Sathyanath S, Kundapur R, Deepthi R, Poojary SN, Rai S, Modi B, et al. An economic evaluation of diabetes mellitus in India: A systematic review. Diabetes Metab Syndr. 2022;16(11):102641.
Hirsch I B, Riddle M C. Current therapies for diabetes. Endocrinol Metab Clin N Ame. 1997; 26:511–678.
Saini JS, Garg MK. Insulin and OHA: Days of coalition therapy. API Med Update. 1999;9(11):287–299.
Heine RJ. Insulin treatment of non-insulin-dependent diabetes mellitus. Baillieres Clin Endocrinol Metab. 1988;2(2):477-92.
Hu C, Jia W. Diabetes in China: Epidemiology and Genetic Risk. Factors and Their Clinical Utility in Personalized Medication. Diab. 2018;67(1):3–11.
Singla R, Bindra J, Singla A, Gupta Y, Kalra S. Drug Prescription Patterns and Cost Analysis of Diabetes Therapy in India: Audit of an Endocrine Practice. Indian J Endocrinol Metab. 2019;23(1):40–45.
Pappachan J M, Fernandez C J, Chacko E. C. Diabesity and Antidiabetic Drugs. Mol Aspects Med. 2019;66:3–12.
Tiwari K, Bisht M, Kant R, Handu SS. Prescribing pattern of anti-diabetic drugs and adherence to the American Diabetes Association’s (ADA) 2021 treatment guidelines among patients of type 2 diabetes mellitus: A cross-sectional study. J Family Med Prim Care. 2022;11(10):6159-6164.
Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-5457.
McGettigan P, Roderick P, Mahajan R, et al. Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med. 2015;12(5):e1001826.
Evans V, Roderick P, Pollock AM. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India. BMJ Glob Health. 2018;3(2):e000263.
Fatima Z, Atal S, Joshi R, Sadasivam B. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India. Cureus. 2022;14(2): e22141.
Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Des Devel Ther. 2023;17:1907-1932.
Venkateswaramurthy N, Shajeem S, Sambathkumar R: Prescribing pattern of antidiabetic drugs in type-2 diabetic patients. Int J Pharm Sci Res. 2016; 7(11):4550-55.
Shanthi M. A study of drug utilization pattern and pharmacoeconomic of antidiabetic drugs in patients attending a teaching hospital. Int J Basic Clin Pharmacol. 2018; (4):796-801.
Lokhandwala T, Smith N, Sternhufvud C, Sörstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203-12.
Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of antidiabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharma. 2014;5:79-83.
Dumoulin J, Kaddar M, Velásquez G. Guide to Drug Financing Mechanisms. World Health Organization Geneva. 1998.
Sola D, Rossi L, Schianca G P, Maffioli P, Bigliocca M, Mella R et al. Sulfonylureas and Their Use in Clinical Practice. Arch Med Sci. 2015; 11(4):840–848.
Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML et al. Mortality and Cardiovascular Risk Associated with Different Insulin Secretagogues Compared with Metformin in Type 2 Diabetes, with or without a Previous Myocardial Infarction: A Nationwide Study. Eur Heart J. 2011;32(15):1900–1908.
Rao A D, Kuhadiya N, Reynolds K, Fonseca V A. Is the Combination of Sulfonylureas and Metformin Associated with an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: a Meta-Analysis of Observational Studies. Diabetes Care. 2008;31(8):1672–1678.
Hans N, Kaur P. A prospective study on prescribing pattern in type 2 diabetes mellitus outpatients in a tertiary care institution. Int J Med Sci Diag Res. 2020;4(7):44-7.
Dadhich J, Dadhich D, Dadheech R, Gupta N, Chandel R, Kakkar S. Prescribing patterns in type 2 diabetes mellitus outpatients at a tertiary care centre in Jaipur, India. Scr Med. 2022;53(2):130-4.
Kiran P G, Anil S P, Karmur M. Prescription pattern and cost variation analysis in type 2 diabetes mellitus patients at private outpatient department. J Basic Clin Pharm. 2021;12: 11-14.
Ramasamy D, Geetha AD, Siddiq Jamal Ahamed Y, Abdul Rahman Noori T, Sahadevan I, Natarajan HM et al. Analysis of fixed dose combinations and price variations of oral antidiabetic agents in the Indian pharmaceutical market. Indian J Pharm Pharmacol. 2024;11(4):213-220.
Chanthran N, Ming L C, Tan C S, Menon S, Kaur J H, Kalusalingam A et al. Prescribing trend and drug cost analysis of oral hypoglycemic agents using drug utilisation review. Malaysian J Pub H Med. 2020;20(2):261–267
Goyal P K, Arora S, Mittal N, Mahajan B, Kaushal S. Prescribing pattern and pharmacoeconomic analysis of antidiabetic drugs. Int J Basic Clin Pharmacol. 2019;8(8):1844–1849.
| Issue | Vol 13, No 3 (Summer 2025) | |
| Section | Brief Report | |
| DOI | https://doi.org/10.18502/jpc.v13i3.20324 | |
| Keywords | ||
| Metformin Cost Variation Analysis Fixed-Dose Combinations | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
